Bone resorption by osteoclasts is coupled with bone formation by osteoblasts,
and this balanced process continuously remodels and adapts the skeleton. The
receptor activator of nuclear factor κB ligand (RANKL) has been identified
as an essential cytokine for the formation and activation of osteoclasts.
The effects of RANKL are physiologically counterbalanced by the decoy receptor
osteoprotegerin (OPG). Estrogen deficiency, glucocorticoid exposure, T-cell
activation (eg, rheumatoid arthritis), and skeletal malignancies (eg, myeloma,
metastases) enhance the ratio of RANKL to OPG and, thus, promote osteoclastogenesis,
accelerate bone resorption, and induce bone loss. Moreover, alterations of
the OPG/RANKL/RANK system have been implicated in vascular diseases. RANKL
blockade (using OPG or RANK fusion proteins or RANKL antibodies) has prevented
bone loss caused by osteoporosis, chronic inflammatory disorders, and malignant
tumors in animal models and may emerge as a therapy in humans based on studies
in postmenopausal osteoporosis, myeloma bone disease, and osteolytic metastases.
This review summarizes the clinical implications of the OPG/RANKL/RANK system
for bone and vascular diseases.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 403
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.